Adaptimmune Therapeutics PLC Quarterly Income Tax Expense (Benefit) in USD from Q1 2015 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
Adaptimmune Therapeutics PLC quarterly/annual Income Tax Expense (Benefit) history and growth rate from Q1 2015 to Q3 2024.
  • Adaptimmune Therapeutics PLC Income Tax Expense (Benefit) for the quarter ending September 30, 2024 was $831K, a 21% increase year-over-year.
  • Adaptimmune Therapeutics PLC Income Tax Expense (Benefit) for the twelve months ending September 30, 2024 was $1.23M, a 58.9% decline year-over-year.
  • Adaptimmune Therapeutics PLC annual Income Tax Expense (Benefit) for 2023 was $1.34M, a 46.5% decline from 2022.
  • Adaptimmune Therapeutics PLC annual Income Tax Expense (Benefit) for 2022 was $2.5M, a 216% increase from 2021.
  • Adaptimmune Therapeutics PLC annual Income Tax Expense (Benefit) for 2021 was $791K, a 388% increase from 2020.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $1.23M $831K +$144K +21% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-13
Q2 2024 $1.08M $526K -$154K -22.6% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-12
Q1 2024 $1.24M $526K -$99K -15.8% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-15
Q4 2023 $1.34M -$656K -$1.65M -166% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-06
Q3 2023 $2.99M $687K +$288K +72.2% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-13
Q2 2023 $2.7M $680K +$210K +44.7% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-12
Q1 2023 $2.49M $625K -$9K -1.42% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-15
Q4 2022 $2.5M $994K +$785K +376% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-06
Q3 2022 $1.71M $399K +$191K +91.8% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-08
Q2 2022 $1.52M $470K +$394K +518% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-09
Q1 2022 $1.13M $634K +$336K +113% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-12
Q4 2021 $791K $209K +$157K +302% Oct 1, 2021 Dec 31, 2021 10-K 2024-03-06
Q3 2021 $634K $208K +$193K +1287% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-08
Q2 2021 $441K $76K +$51K +204% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 $390K $298K +$228K +326% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-09
Q4 2020 $162K $52K -$36K -40.9% Oct 1, 2020 Dec 31, 2020 10-K 2023-03-06
Q3 2020 $198K $15K -$72K -82.8% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 $270K $25K -$40K -61.5% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-09
Q1 2020 $310K $70K +$68K +3400% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q4 2019 $242K $88K -$47K -34.8% Oct 1, 2019 Dec 31, 2019 10-K 2022-03-14
Q3 2019 $289K $87K -$46K -34.6% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 $335K $65K -$37K -36.3% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-06
Q1 2019 $372K $2K -$125K -98.4% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-14
Q4 2018 $497K $135K +$305K Oct 1, 2018 Dec 31, 2018 10-K 2021-02-25
Q3 2018 $192K $133K -$92K -40.9% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-06
Q2 2018 $284K $102K -$63K -38.2% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-01
Q1 2018 $347K $127K -$104K -45% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-06
Q4 2017 $451K -$170K -$606K -139% Oct 1, 2017 Dec 31, 2017 10-K 2019-02-27
Q3 2017 $1.06M $225K +$121K +116% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-06
Q2 2017 $936K $165K -$128K -43.7% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-02
Q1 2017 $1.06M $231K +$172K +292% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-09
Q4 2016 $892K $436K Oct 1, 2016 Dec 31, 2016 10-K 2019-02-27
Q3 2016 $104K +$84K +420% Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-02
Q2 2016 $293K +$146K +99.3% Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-03
Q1 2016 $59K +$8K +15.7% Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-10
Q3 2015 $20K Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-10
Q2 2015 $147K Apr 1, 2015 Jun 30, 2015 10-Q 2016-08-08
Q1 2015 $51K Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.